Related Experiment Video
Updated: Jun 14, 2025
07:39
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
39
TP53-mutated acute myeloid leukemia: how can we improve outcomes?
David A Sallman1, Maximilian Stahl2
1Malignant Hematology Department, Moffitt Cancer Center, Tampa, FL.
Blood
|September 5, 2024
Summary
TP53-mutated acute myeloid leukemia (AML) remains a challenging subgroup with poor outcomes. New international clinical interventions are crucial to improve the standard of care for these patients.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute myeloid leukemia (AML) treatment has advanced, but TP53-mutated AML shows no survival improvement.
- TP53-mutated AML patients have a median overall survival of approximately 6 months, irrespective of age or fitness.
- Understanding the biology and prognostication of TP53-mutated AML has advanced.
Purpose of the Study:
- To highlight the persistent challenges in treating TP53-mutated AML.
- To emphasize the need for novel therapeutic strategies.
- To call for international collaboration to improve patient outcomes.
Main Methods:
- Review of current treatment paradigms for AML.
- Analysis of prognostic factors in TP53-mutated AML.
- Synthesis of recent biological and clinical findings.
Main Results:
- TP53-mutated AML remains a high-risk subgroup with dismal survival rates.
- Current treatments have not significantly altered the prognosis for this patient group.
- Biological insights and classification advancements have been made.
Conclusions:
- TP53-mutated AML requires urgent development of novel clinical interventions.
- International collaborative efforts are essential to change the standard of care.
- Improved therapies are critically needed to alter the poor survival outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K